Total Debt Summary of InnoPharmax Inc.

InnoPharmax Inc.'s latest annual total debt in 2023 was 21.49 Million TWD , down -42.75% from previous year.
InnoPharmax Inc.'s latest quarterly total debt in 2024 Q2 was 10 Million TWD , up 34.49% from previous quarter.
InnoPharmax Inc. reported annual total debt of 37.55 Million TWD in 2022, up 573.75% from previous year.
InnoPharmax Inc. reported annual total debt of 5.57 Million TWD in 2021, down -81.36% from previous year.
InnoPharmax Inc. reported quarterly total debt of 10 Million TWD for 2024 Q2, up 34.49% from previous quarter.
InnoPharmax Inc. reported quarterly total debt of 21.49 Million TWD for 2023 FY, down -42.75% from previous quarter.

Annual Total Debt Chart of InnoPharmax Inc. (2023 - 2019)

Name	Total Debt	Total Debt Difference
Allied Biotech Corporation	796.6 Million TWD	97.301%
GeneFerm Biotechnology Co., Ltd.	152.07 Million TWD	85.863%
Easywell Biomedicals, Inc.	386.34 Million TWD	94.435%
TTY Biopharm Company Limited	1.91 Billion TWD	98.877%
Synmosa Biopharma Corporation	2.43 Billion TWD	99.119%
Orient EuroPharma Co., Ltd.	4.84 Billion TWD	99.556%
Center Laboratories, Inc.	5.62 Billion TWD	99.618%
Tien Liang BioTech Co., Ltd.	84.65 Million TWD	74.605%
Orient Pharma Co., Ltd.	716.92 Million TWD	97.001%
Johnson Chemical Pharmaceutical Works Co., Ltd.	160.83 Million TWD	86.633%
Excelsior Biopharma Inc.	377.4 Million TWD	94.303%
DV Biomed Co., Ltd.	387.69 Million TWD	94.455%
Foresee Pharmaceuticals Co., Ltd.	228.25 Million TWD	90.581%
Handa Pharmaceuticals, Inc.	13.24 Million TWD	-62.379%
UniPharma Co., Ltd.	277 Thousand TWD	-7661.372%
Anxo Pharmaceutical Co., Ltd.	787.84 Million TWD	97.271%
Alar Pharmaceuticals Inc.	1.4 Million TWD	-1425.834%
Winston Medical Supply Co., Ltd.	107.32 Million TWD	79.969%
Mercury Biopharmaceutical Corporation	42.34 Million TWD	49.234%
Bioray Biotech Co., Ltd	69.79 Million TWD	69.196%
TSH Biopharm Corporation Limited	7.84 Million TWD	-174.117%